HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy

AIDS

Volumn 27, Issue 8, 2013, Pages 1231-1238

  Guzmán Fulgencio, María ^a   Berenguer, Juan ^b   Rallón, Norma ^c   Fernández Rodríguez, Amanda ^a   Miralles, Pilar ^b   Soriano, Vicente ^c   Jiménez Sousa, María A ^a   Cosín, Jaime ^b   Medrano, Jose ^c   García Álvarez, Mónica ^a   López, Juan C ^b   Benito, José M ^c   Resino, Salvador ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

AIDS; Hepatitis C virus clearance; Hepatitis C virus therapy; HLA E; IL28B; Single nucleotide polymorphism

Indexed keywords

HLA E ANTIGEN; PEGINTERFERON ALPHA; RIBAVIRIN;

ALLELE; ANTIVIRAL THERAPY; ARTICLE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; ALLELES; ANTIVIRAL AGENTS; COINFECTION; FEMALE; FOLLOW-UP STUDIES; GENOTYPING TECHNIQUES; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; VIRAL LOAD;

EID: 84879087627     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835f5b9c     Document Type: Article

References (34)

1. Mocroft A, Ledergerber B, Katlama C., Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
2. Lewden C, May T, Rosenthal E., Burty C, Bonnet F, Costagliola D., et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the 'Mortalite 2000 and 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
3. Ghany MG, Strader DB, Thomas D.L., Seeff LB Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
4. Naggie S, Sulkowski MS Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012; 142:1324-1334; e1323.
5. Calvaruso V, Craxi A. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012; 32 (SUPPL. 1):2-8.
6. Soriano V, Poveda E, Vispo E., Labarga P, Rallon N, Barreiro P. Pharmacogenetics of hepatitis C. J Antimicrob Chemother 2012; 67:523-529.
7. Pietra G, Romagnani C, Manzini C., Moretta L, Mingari MC The emerging role of HLA-E-restricted CD8R T lymphocytes in the adaptive immune response to pathogens and tumors. J Biomed Biotechnol 2010; 2010:907092.
8. Pietra G, Romagnani C, Mazzarino P., Falco M, Millo E, Moretta A., et al. HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci U S A 2003; 100:10896-10901.
9. Grimsley C, Ober C. Population genetic studies of HLA-E: evidence for selection. Hum Immunol 1997; 52:33-40.
10. Ulbrecht M, Couturier A, Martinozzi S., Pla M, Srivastava R, Peterson P.A., et al. Cell surface expression of HLA-E: interaction with human beta2-microglobulin and allelic differences. Eur J Immunol 1999; 29:537-547.
11. Nattermann J, Nischalke HD, Hofmeister V, Ahlenstiel G., Zimmermann H, Leifeld L, et al The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol 2005; 166:443-453.
12. Nattermann J, Nischalke HD, Hofmeister V, Kupfer B., Ahlenstiel G, Feldmann G, et al HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells. Antivir Ther 2005; 10:95-107.
13. Lajoie J, Hargrove J, Zijenah L.S., Humphrey JH, Ward BJ, Roger M. Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. J Infect Dis 2006; 193:298-301.
14. Schulte D, Vogel M, Langhans B., Kramer B, Korner C, Nischalke H.D., et al. The HLA-E(R)/HLA-E(R) genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-restricted recognition of an HCV-derived peptide by interferon-gamma-secreting human CD8(+) T cells. J Infect Dis 2009; 200:1397-1401.
15. Suppiah V, Gaudieri S, Armstrong N.J., O'Connor KS, Berg T, Weltman M., et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med 2011; 8:e1001092.
16. Golden-Mason L., Bambha KM, Cheng L, Howell C.D., Taylor MW, Clark PJ, et al Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology 2011; 54:1559-1569.
17. Fernandez-Rodriguez A., Rallon N, Berenguer J., Jimenez-Sousa MA, Cosin J, Guzman-Fulgencio M, et al. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV coinfected patients. AIDS 2013; 27:163-173.
18. Mosaad YM, Abdel-Dayem Y, El-Deek BS, El-Sherbini SM. Association between HLA-E M0101 homozygosity and recurrent miscarriage in Egyptian women. Scand J Immunol 2011; 74:205-209.
19. Soriano V, Puoti M, Sulkowski M., Cargnel A, Benhamou Y, Peters M., et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089.
20. Lunetta KL. Genetic association studies. Circulation 2008; 118:96-101.
21. Strong RK, Holmes MA, Li P, Braun L., Lee N, Geraghty DE HLA-E allelic variants. J Biol Chem 2003; 278:5082-5090.
22. Ahlenstiel G, Titerence RH, Koh C, Edlich B., Feld JJ, Rotman Y, et al Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010; 138:325-335; e321-322.
23. Costa P, Rusconi S, Mavilio D., Fogli M, Murdaca G, Pende D., et al. Differential disappearance of inhibitory natural killer cell receptors during HAART and possible impairment of HIV-1-specific CD8 cytotoxicTlymphocytes. AIDS 2001; 15:965-974.
24. Zhang R, Xu J, Hong K., Yuan L, Peng H, Tang H., et al. Increased NKG2A foundincytotoxic natural killer subset in HIV-1 patients with advanced clinical status. AIDS 2007; 21 (SUPPL. 8):S9-S17.
25. Brunetta E, Fogli M, Varchetta S., Bozzo L, Hudspeth KL, Marcenaro E, et al Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection. AIDS 2010; 24:27-34.
26. Jiménez-Sousa M.A., Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S. Meta-analysis: implications of IL28B polymorphisms in spontaneous and treatment-related clearance for hepatitis C patients. BMC Med 2013; 11:6.
27. Holmes JA, Desmond PV, Thompson AJ Redefining baseline demographics: the role of genetic testing in hepatitis C virus infection. Clin Liver Dis 2011; 15:497-513.
28. Payer BA, Reiberger T, Aberle J., Ferenci P, Holzmann H, Rieger A., et al. IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur J Clin Invest 2012; 42:599-606.
29. Fattovich G, Covolo L, Bibert S., Askarieh G, Lagging M, Clement S., et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33:1162-1172.
30. Lagging M, Askarieh G, Negro F., Bibert S, Soderholm J, Westin J., et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011; 6:e17232.
31. Darling JM, Aerssens J, Fanning G., McHutchison JG, Goldstein DB, Thompson AJ, et al Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011; 53:14-22.
32. Marcello T, Grakoui A, Barba-Spaeth G, Machlin E.S., Kotenko SV, MacDonald MR, et al Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131:1887-1898.
33. Hayes CN, Imamura M, Aikata H., Chayama K. Genetics of IL28B and HCV: response to infection and treatment. Nat Rev Gastroenterol Hepatol 2012; 9:406-417.
34. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011; 60:1284-1293. en Espana